Early Stage Life Science Investors Converge on Boston

Monday, March 24th, 2014 - The State Room, Boston, MA

The RESI conference will be one of the more unique events in the life sciences space this coming year. This full-day investor partnering conference is groundbreaking in that it is focused on redefining the investor landscape in early stage life sciences. The life science investor landscape has changed; venture capital has left a void and there is a plethora of new entities entering the space with capital to allocate.

This conference has assembled these players - Senior decision-makers from some of the largest pharmaceutical & device companies, patient groups, philanthropic organizations, investment banks, and family offices will all be joining the action on March 24th. The conference will also have representation from next-generation technology transfer, licensing and funding experts, and there will be a series of free workshops. We urge all of our members to take a look at the program, and to take some time out to reeducate themselves regarding the new landscape unfolding in the life science investor arena. Registration and sponsorship information is available at www.resiconference.com.

Contact:
Maximilian Klietmann
Partner / VP of Marketing
Life Science Nation (LSN)
9B Hamilton Place
Boston, MA, 02108
Office: 617.600.3076 ext. 1005
Mobile: 617.686.2403
Email: [email protected]

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.